Market Overview

Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival


Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of ALIMTA® (pemetrexed for injection) with bevacizumab (AVASTIN®) and carboplatin induction followed by ALIMTA plus bevacizumab maintenance–the ALIMTA arm–compared to the combination of paclitaxel with bevacizumab and carboplatin followed by bevacizumab maintenance–the paclitaxel arm.

The study did meet one of its secondary endpoints of improved progression-free survival for the ALIMTA arm. Results will be presented on September 7 at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

Posted-In: News FDA


Related Articles (LLY)

View Comments and Join the Discussion!

Partner Center